- Home
- ICAD vs SKYE Comparison
ICAD vs SKYE Comparison
Compare ICAD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICAD
- SKYE
- Stock Information
- Founded
- ICAD 1984
- SKYE 2012
- Country
- ICAD United States
- SKYE United States
- Employees
- ICAD N/A
- SKYE N/A
- Industry
- ICAD Medical/Dental Instruments
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ICAD Health Care
- SKYE Health Care
- Exchange
- ICAD Nasdaq
- SKYE Nasdaq
- Market Cap
- ICAD 87.5M
- SKYE 80.7M
- IPO Year
- ICAD 1986
- SKYE N/A
- Fundamental
- Price
- ICAD $1.98
- SKYE $1.40
- Analyst Decision
- ICAD
- SKYE Buy
- Analyst Count
- ICAD 0
- SKYE 7
- Target Price
- ICAD N/A
- SKYE $18.00
- AVG Volume (30 Days)
- ICAD 274.2K
- SKYE 216.6K
- Earning Date
- ICAD 03-19-2025
- SKYE 03-20-2025
- Dividend Yield
- ICAD N/A
- SKYE N/A
- EPS Growth
- ICAD N/A
- SKYE N/A
- EPS
- ICAD N/A
- SKYE N/A
- Revenue
- ICAD $19,608,000.00
- SKYE N/A
- Revenue This Year
- ICAD $2.39
- SKYE N/A
- Revenue Next Year
- ICAD $13.71
- SKYE N/A
- P/E Ratio
- ICAD N/A
- SKYE N/A
- Revenue Growth
- ICAD 13.22
- SKYE N/A
- 52 Week Low
- ICAD $1.18
- SKYE $1.37
- 52 Week High
- ICAD $3.78
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- ICAD 36.58
- SKYE 27.90
- Support Level
- ICAD $2.05
- SKYE $2.08
- Resistance Level
- ICAD $2.48
- SKYE $2.44
- Average True Range (ATR)
- ICAD 0.16
- SKYE 0.29
- MACD
- ICAD -0.01
- SKYE -0.07
- Stochastic Oscillator
- ICAD 5.66
- SKYE 2.11
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.